Epigallocatechin-3-gallate (EGCG) for clinical trials

• Verfasst von: Mereles, Derliz [VerfasserIn]
• Verfasst von: Hunstein, Werner [VerfasserIn]
• Titel: Epigallocatechin-3-gallate (EGCG) for clinical trials
• Titelzusatz: more pitfalls than promises?
• Verf.angabe: Derliz Mereles and Werner Hunstein
• E-Jahr: 2011
• Jahr: 31 August 2011
• Umfang: 12 S.
• Fussnoten: Gesehen am 18.08.2022
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2011
• Band/Heft Quelle: 12(2011), 9, Seite 5592-5603
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms12095592
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bioavailability
• Sach-SW: epigallocatechin-3-gallate
• Sach-SW: green tea
• K10plus-PPN: 1814671552

Abstract

Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined.